Integrating epidemiology, psychology, and economics to achieve HPV vaccination targets

Human papillomavirus (HPV) vaccines provide an opportunity to reduce the incidence of cervical cancer. Optimization of cervical cancer prevention programs requires anticipation of the degree to which the public will adhere to vaccination recommendations. To compare vaccination levels driven by public perceptions with levels that are optimal for maximizing the community's overall utility, we develop an epidemiological game-theoretic model of HPV vaccination. The model is parameterized with survey data on actual perceptions regarding cervical cancer, genital warts, and HPV vaccination collected from parents of vaccine-eligible children in the United States. The results suggest that perceptions of survey respondents generate vaccination levels far lower than those that maximize overall health-related utility for the population. Vaccination goals may be achieved by addressing concerns about vaccine risk, particularly those related to sexual activity among adolescent vaccine recipients. In addition, cost subsidizations and shifts in federal coverage plans may compensate for perceived and real costs of HPV vaccination to achieve public health vaccination targets.

[1]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[2]  M. Stein.  Large sample properties of simulations using latin hypercube sampling , 1987 .

[3]  W. Edmunds,et al.  Cost-effectiveness analyses of human papillomavirus vaccination. , 2007, The Lancet. Infectious diseases.

[4]  E. Barr,et al.  Quadrivalent-human-papillomavirus-vaccine , 2007, Reactions Weekly.

[5]  R. Insinga.  Annual productivity costs due to cervical cancer mortality in the United States. , 2006, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[6]  C. Bauch.  Imitation dynamics predict vaccinating behaviour , 2005, Proceedings of the Royal Society B: Biological Sciences.

[7]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  A. Galvani,et al.  Vaccination against multiple HPV types. , 2005, Mathematical biosciences.

[9]  E. Dasbach,et al.  The health and economic burden of genital warts in a set of private health plans in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Douglas K Owens,et al.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.

[11]  Carl W. Miller,et al.  Mutations of p53 and human papillomavirus infection in cervical carcinoma , 1993, Cancer.

[12]  D. Earn,et al.  Vaccination and the theory of games. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Neumann,et al.  Theory of games and economic behavior , 1945, 100 Years of Math Milestones.

[14]  Andrew Gelman,et al.  General methods for monitoring convergence of iterative simulations , 1998 .

[15]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[16]  N. Welton,et al.  Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[17]  Elamin H Elbasha,et al.  Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.

[18]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[19]  Timothy C. Reluga,et al.  Evolving public perceptions and stability in vaccine uptake. , 2006, Mathematical biosciences.

[20]  Gillian D. Sanders,et al.  Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.

[21]  C. D. Gelatt,et al.  Optimization by Simulated Annealing , 1983, Science.

[22]  DoubleTree Hotel Atlanta.  DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL ADVISORY COMMITTEE FOR INJURY PREVENTION AND CONTROL , 2006 .

[23]  Guoyu Tao,et al.  The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. , 2004, Perspectives on sexual and reproductive health.

[24]  Allison L. Friedman,et al.  Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. , 2008, Health education & behavior : the official publication of the Society for Public Health Education.

[25]  R. Lawrence,et al.  COMMITTEE TO STUDY PRIORITIES FOR VACCINE DEVELOPMENT , 2000 .

[26]  J. Seward,et al.  Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[27]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[28]  Karen M Kuntz,et al.  Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.

[29]  D. Earn,et al.  Group interest versus self-interest in smallpox vaccination policy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Marie-Claude Boily,et al.  Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. , 2007, American journal of epidemiology.

[31]  S. Basu,et al.  Re: "Multiparameter calibration of a natural history model of cervical cancer". , 2007, American journal of epidemiology.

[32]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[33]  J M Robins,et al.  Identifiability, exchangeability, and epidemiological confounding. , 1986, International journal of epidemiology.

[34]  S. H. Murdock,et al.  Income, poverty, and health insurance coverage in the United States, 2008. , 2009 .

[35]  Elizabeth R Unger,et al.  Prevalence of HPV infection among females in the United States. , 2007, JAMA.

[36]  J. Nash.  Equilibrium Points in N-Person Games. , 1950, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Coye,et al.  America's Children: Health Insurance and Access to Care , 1998 .

[38]  A. Glass,et al.  Diagnoses and outcomes in cervical cancer screening: a population-based study. , 2004, American journal of obstetrics and gynecology.

[39]  Timothy C. Reluga,et al.  Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum , 2007, Proceedings of the National Academy of Sciences.

[40]  Jan Medlock,et al.  Optimal Timing of Disease Transmission in an Age-Structured Population , 2007, Bulletin of mathematical biology.

[41]  D. Ekwueme,et al.  Cost-effectiveness of Human Papillomavirus Vaccination in the United States , 2008, Emerging infectious diseases.

[42]  M. Weinstein,et al.  A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.

[43]  N. Grassly,et al.  Mathematical models of infectious disease transmission , 2008, Nature Reviews Microbiology.

[44]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[45]  J. Colgrove.  The ethics and politics of compulsory HPV vaccination. , 2006, The New England journal of medicine.

[46]  L. G. Koss,et al.  Cervical Cancer , 1981, Current Topics in Pathology.